Related references
Note: Only part of the references are listed.Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts
Pietro Bertino et al.
CLINICAL CANCER RESEARCH (2008)
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
Martee L. Hensley et al.
GYNECOLOGIC ONCOLOGY (2008)
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine lelomyosarcoma: A Gynecologic Oncology Group phase II trial
Martee L. Hensley et al.
GYNECOLOGIC ONCOLOGY (2008)
Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial
Vassilis Georgoulias et al.
LUNG CANCER (2008)
Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - A single-center experience
Peter Ebeling et al.
ONKOLOGIE (2008)
Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors
Yaqoob Ali et al.
CLINICAL CANCER RESEARCH (2007)
Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer:: a lung cancer Galician group phase II study
Joaquin Casal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas
Robert G. Maki et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck - A phase II multicenter study
Jean-Luc Labourey et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2007)
Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours
Suzanne George et al.
EUROPEAN JOURNAL OF CANCER (2006)
A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer
K Matsui et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2005)
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: Results of a multicenter phase II study
S Palmeri et al.
ONCOLOGY (2005)
Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib
M Breccia et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: Results of a multicenter phase II study
M Brandi et al.
SEMINARS IN ONCOLOGY (2004)
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer
P Mathew et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group
F Fossella et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Unexpected pleural effusions in 3 pediatric patients treated with STI-571
R Goldsby et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2002)
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors
H Dumez et al.
ANTI-CANCER DRUGS (2002)
Imatinib mesylate (ST1571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
HM Kantarjian et al.
BLOOD (2002)
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: A Hoosier Oncology Group study
KN Ganjoo et al.
ONCOLOGY (2002)
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer
P Bhargava et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer
AM Murad et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer:: a multicentre phase II study
JY Douillard et al.
BRITISH JOURNAL OF CANCER (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients
RA Nagourney et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
D Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
